CAUTION: Federal Law prohibits dispensing without prescription
lsoxsuprine HCI occurs as a white odorless, crystalline powder, having a bittertaste, It has a following structural formula
Based on a review of this drug by the National Academy of Sciences -National Research Council and / or other information, the FDA has classified the medications as follows :
Possibly Effective :1. For the relief of symptoms associated with cerebral vascular insufficiency2. In peripheral vascular disease of arteriosclerosis obliterans, thromboangitis obliterans (Buerger's Disease) and Raynaud's disease.
Final classification of the less than - effective indications requires further investigation.
Each tablet contains lsoxsuprine HCI 20 mg.
There are no known contraindications to oral use when administered in recommended doses. Should not be given immediately postpartum or in the presence of arterial bleeding.
On rare occasions oral administration of the drug has been associated in time with the occurrences of hypotension, tachycardia, nausea, vomiting, dizziness, abdominal distress, and severe rash. If rash appears the drug should be discontinued.Although available evidence suggests a temporal association of these reactions with Isoxsuprine, a casual relationship can be neither confirmed nor refused.
10 to 20mg three or four times daily
lsoxsuprine HCI 20mg tablets are supplied in HDPE containers of 1,000's
Manufactured in India byVista Pharmaceuticals, Limited.